Ocugen has a broad pipeline which includes both clinical stage and pre-clinical programs addressing large areas of unmet medical need. Our programs are focused on activating novel biologic pathways to treat inflammatory, degenerative, and neovascular diseases of the eye and are designed to deliver value over the near, mid and long term.
Latest Press Releases
Announces License Agreement with University of Illinois at Chicago (UIC) for OCU300; Patent Allowed for OCU200, Novel, Preclinical Biologic in Development for Wet AMD
Company Announces Executive Management, Board and Scientific Advisory Board Updates